Erratum: Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients (International Urology and Nephrology DOI: 10.1007/s11255-011-0007-x);Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients

International Urology and Nephrology

Volumn 44, Issue 4, 2012, Pages 1193-1199

  NasrAllah, Mohamed M ^a   El Shehaby, Amal R ^b   Osman, Noha A ^a   Salem, Mona M ^a   Nassef, Amr ^a   Sharaf El Din, Usama A A ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Advanced glycation end products; CKD MBD; HsCRP; Inflammation; RAGE; Vascular calcification

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; LIPID; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ADULT; AORTIC CALCIFICATION INDEX; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN FUNCTION; SYNDROME DELINEATION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

EID: 84867901183     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0067-y     Document Type: Erratum

References (37)

1. Adragäo T, Pires A, Birne R et al (2009) A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant 24:997-1002
2. Okuno S, Ishimura E, Kitatani K et al (2007) Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49:417-425
3. London GM, Gue'rin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740
4. Cannata-Andía JB, Rodríguez-García M, Carrillo-López N et al (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17:267-273
5. GoodmanW and London G (2004) (on behalf of the vascular calcification Work Group). Vascular calcification in chronic kidney disease. Am J Kid Dis. 43:572-9
6. NasrAllah MM, El-Shehaby AR, Salem MM et al (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 25:2679-2685
7. Ketteler M (2005) Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14(4):337-342
8. Jono S, Shioi A, Ikari Y, Nishizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24(2):176-181
9. Nikolov I, Joki N, Drueke T et al (2006) Beyond phosphate - role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant 21:3354-3357
10. Meerwaldt R, Zeebregts CJ, Navis G et al (2009) Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 53:138-150
11. Yan SF, Ramasamy R, Schmidt AM (2010) Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79:1379-1386
12. Basta G, Leonardis D, Mallamaci F et al (2010) Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 77:225-231
13. Vazzana N, Santilli F, Cuccurullo C et al (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4:389-401
14. Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196:9-21
15. Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204:288-292
16. Choi KM, Yoo HJ, Kim HY et al (2009) Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132:96-101
17. Nishizawa Y, Koyama H (2008) Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr 18:76-82
18. Koyama H, Yamamoto H, Nishizawa Y (2007) Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2:331-339
19. Yamagishi S, Fujimori H, Yonekura H et al (1999) Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 258:353-357
20. Ren X, Shao H, Wei Q et al (2009) Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 37:847-854
21. Sigrist M, Bungay P, Taal MW et al (2006) Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 21:707-714
22. Basta G, Corciu AI, Vianello A et al (2010) Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 210:614-618
23. Taniwaki H, Ishimura E, Tabata T et al (2005) Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 20:2472-2478
24. Kabaya T, Nitta K, Kimura H et al (1999) Increased aortic calcification index in hemodialysis patients. Nephron 81:354-355
25. Maillard-Lefebvre H, Boulanger E et al (2009) Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48:1190-1196
26. Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901
27. Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38(Suppl 1):S100-S106
28. Hori O, Yan SD, Ogawa S et al (1996) The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 11(Suppl 5):13-16
29. Nin JW, Ferreira I, Schalkwijk CG et al (2009) EURODIAB Prospective complications study group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective complications study. Diabetologia 52:705-714
30. McNair ED, Wells CR, Mabood Qureshi A et al (2010) Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 341:135-138
31. Kalousová M, Hodková M, Kazderová M et al (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406-411
32. Jachymova M, Mestek O, Hodkova M et al (2007) Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020-2026
33. Massy ZA, Maziere C, Kamel S et al (2005) Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 20:380-382
34. Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95:560-567
35. Jean G, Bresson E, Terrat J et al (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948-955
36. Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204:288-292
37. Bellasi A, Raggi P (2007) Techniques and technologies to assess vascular calcification. Semin Dial 20:129-133